Key Highlights

  • Loss per share was USD 0.74 against an estimated loss of USD 0.84, with no Revenue reported.
  • Cash, equivalents and short-term investments totaled USD 289.6 million, plus USD 24.2 million of long-term investments.
  • The REZILIENT3 Phase 3 trial of zipalertinib met its primary endpoint at interim analysis in first-line lung cancer.
  • The FDA's action date for the zipalertinib monotherapy application is February 27, 2027, per the filing.

Cullinan Therapeutics (NASDAQ:CGEM) reported a third quarter 2026 loss of USD 0.74 per share, narrower than the USD 0.84 estimate, with no revenue. At September 30 the company held USD 289.6 million in cash, cash equivalents and short-term investments, plus USD 24.2 million of Long-Term Investments and interest receivable, against an accumulated Deficit of USD 740.9 million. It made no sales under its at-the-market program through September 30.

General and administrative expenses for the nine months fell USD 5.1 million from the prior-year period, mainly on lower equity-based compensation of USD 4.8 million, legal costs of USD 0.5 million and professional fees of USD 0.4 million, partly offset by higher personnel costs of USD 0.7 million.

Zipalertinib Moves Toward Filing and Approval

The global Phase 3 REZILIENT3 trial, which pairs zipalertinib with platinum-based chemotherapy as first-line treatment for locally advanced or metastatic EGFR exon 20 insertion lung cancer, met its primary endpoint at an interim analysis. In October 2026 the company initiated a New Drug Application submission for that use under the FDA's Real-Time Oncology Review program.

Separately, a New Drug Application seeking Accelerated Approval for zipalertinib as a monotherapy in patients previously treated with platinum-based chemotherapy remains under FDA review, supported by the Phase 2b portion of the REZILIENT1 trial. The FDA's Prescription Drug User Fee Act target action date for that application is February 27, 2027. The company's partner Taiho is referenced in the filing in connection with the program.

Autoimmune and Oncology Pipeline

In autoimmune disease, the company is running the Phase 1 OUTRACE program for CLN-978 in systemic lupus erythematosus, rheumatoid arthritis and Sjögren's disease. Initial data in lupus and rheumatoid arthritis were shown at the EULAR congress, and multi-dose data in rheumatoid arthritis were presented at an investor event in June. In December 2026 the company plans to share single target dose data across all three conditions, along with initial multi-dose regimen data focused on clinical activity, biomarkers and safety.

Velinotamig, a BCMA-by-CD3 T cell engager licensed from Genrix, entered a global Phase 1/2 basket trial in immune thrombocytopenia and warm autoimmune hemolytic anemia, while Genrix is enrolling a Phase 1/2 trial in China, initially in lupus. Lupus data from that work were presented at the American College of Rheumatology Convergence 2026.

For CLN-049 in acute myeloid leukemia, a potentially registrational Phase 2 trial began in October 2026 after a positive end-of-Phase 1 meeting with the FDA in July, including a dose-optimization phase and expansion at the recommended dose. A Phase 1/2 trial combining CLN-049 with venetoclax and azacitidine in newly diagnosed patients began in November.

Regulatory and Data Milestones to Watch

The key dates are the December 2026 autoimmune data release, progress of the zipalertinib first-line application under real-time review, and the February 27, 2027 action date on the monotherapy filing. Enrollment progress in the registrational acute myeloid leukemia trial is another marker.

The company's cash position and the pace of spending as late-stage programs expand are the financial items to follow.